trending Market Intelligence /marketintelligence/en/news-insights/trending/vw6DKG-7Kf7mxlH84Wa4dw2 content esgSubNav
In This List

Ampio's knee osteoarthritis injection effective in phase 3 trial

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Ampio's knee osteoarthritis injection effective in phase 3 trial

Ampio Pharmaceuticals, Inc.'s knee osteoarthritis injection Ampion met its primary goal in a phase 3 trial with 71% of patients reporting improvement in pain, function and quality of life.

Osteoarthritis is an incurable and progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments and bone.

The patient response in the trial exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee.

On average, patients saw a 53% decrease in pain, 50% improvement in function and a 45% improvement in quality of life.

If approved, Ampion would be the first intra-articular injection to treat osteoarthritis of the knee. Ampion is also a non-opioid treatment.

The company is preparing to submit a biologics license application to the U.S. Food and Drug Administration.